KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Short term Debt (2016 - 2025)

Historic Short term Debt for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Abbott Laboratories' Short term Debt fell 3755.8% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 3755.8%. This contributed to the annual value of $1.5 billion for FY2024, which is 3888.89% up from last year.
  • Per Abbott Laboratories' latest filing, its Short term Debt stood at $1.3 billion for Q3 2025, which was down 3755.8% from $507.0 million recorded in Q2 2025.
  • In the past 5 years, Abbott Laboratories' Short term Debt registered a high of $2.3 billion during Q1 2023, and its lowest value of $4.0 million during Q1 2022.
  • In the last 5 years, Abbott Laboratories' Short term Debt had a median value of $1.1 billion in 2023 and averaged $1.2 billion.
  • As far as peak fluctuations go, Abbott Laboratories' Short term Debt tumbled by 9947.09% in 2022, and later soared by 5702500.0% in 2023.
  • Quarter analysis of 5 years shows Abbott Laboratories' Short term Debt stood at $754.0 million in 2021, then soared by 198.54% to $2.3 billion in 2022, then plummeted by 52.02% to $1.1 billion in 2023, then surged by 38.89% to $1.5 billion in 2024, then dropped by 10.33% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $507.0 million for Q2 2025, and $506.0 million during Q1 2025.